Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
This study is currently recruiting participants.
Verified January 2013 by University of Pittsburgh
Sponsor:
University of Pittsburgh
Collaborator:
Merck
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01419678
First received: August 12, 2011
Last updated: January 15, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a single center, observational study of posaconazole PK sampling in lung transplant recipients. The patients enrolled will have up to 6 (3ml) pk samples (a total of 18 ml) and one 10ml blood sample for a total collection of 28ml of blood obtained over the entire study. In addition, the investigators will collect medical record information and any excess BAL samples available during the study (tests done as part of the patient's clinical care and the samples would have been discarded once diagnosis was made).
| Condition | Intervention |
|---|---|
|
Lung Transplant Infection |
Other: collection of blood samples for PK testing |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients |
Resource links provided by NLM:
MedlinePlus related topics:
Lung Transplantation
Drug Information available for:
Posaconazole
U.S. FDA Resources
Further study details as provided by University of Pittsburgh:
Primary Outcome Measures:
- measure the levels of posaconazole post dosing [ Time Frame: 24 hours after dosing ] [ Designated as safety issue: No ]pk samples will be obtained around dosing of medication and then analyzed for posaconazole levels
Secondary Outcome Measures:
- determine the posaconazole concentration within the pulmonary epithelial lining fluid (ELF) and alveolar cells [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 'collection of blood samples for PK testing'
collection of PK samples around a dosing of Posaconazole
|
Other: collection of blood samples for PK testing
PK samples collected around dosing of posaconazole
|
Detailed Description:
PK blood samples will be obtained around a clinical dosing of posaconazole
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 18 years of age and older receiving posaconazole post transplant as part of their care received a lung transplant
Exclusion Criteria:
- must meet inclusion criteria
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01419678
Contacts
| Contact: Ryan Shields, Pharm D | 412-864-3745 | shieldsrk@upmc.edu |
| Contact: Diana Pakstis, RN, BSN | 412-648-6553 | dlp5@pitt.edu |
Locations
| United States, Pennsylvania | |
| UPMC | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Ryan Shields, Pharm D 412-864-3745 shieldsrk@upmc.edu | |
| Contact: Diana Pakstis, RN, BSN 412-648-6553 dlp5@pitt.edu | |
| Principal Investigator: Ryan Shields, Pharm D | |
Sponsors and Collaborators
University of Pittsburgh
Merck
Investigators
| Principal Investigator: | Ryan Shields, Pharm D | University of Pittsburgh |
More Information
No publications provided
| Responsible Party: | University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT01419678 History of Changes |
| Other Study ID Numbers: | PRO10110232 |
| Study First Received: | August 12, 2011 |
| Last Updated: | January 15, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Pittsburgh:
|
posaconazole PK blood sampling |
Additional relevant MeSH terms:
|
Posaconazole Antifungal Agents Anti-Infective Agents Therapeutic Uses |
Pharmacologic Actions Trypanocidal Agents Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on May 21, 2013